STOCK TITAN

CGON insider sale notice: 27,015 shares via Morgan Stanley on NASDAQ

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

CG Oncology, Inc. (CGON) filing a Form 144 to report a proposed sale of common stock. The notice shows 27,015 shares to be sold through Morgan Stanley Smith Barney LLC on 09/05/2025 on NASDAQ with an aggregate market value of $835,844.10 and 76,247,581 shares outstanding. The securities were acquired on 09/05/2025 by exercise of stock options from the issuer, paid in cash. The filer reports no securities sold in the past three months and includes the standard representation that the seller is not aware of undisclosed material adverse information.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Routine insider sale notice reporting option exercise and planned sale of 27,015 shares.

This Form 144 documents a proposed sale tied to an option exercise on the same date, routed through Morgan Stanley Smith Barney LLC for execution on NASDAQ, with an aggregate market value of $835,844.10. The filing indicates no other sales in the past three months and includes the standard attestation about material non-public information. The disclosure appears procedural and consistent with compliance reporting for insiders monetizing exercised options.

TL;DR: Compliance-focused filing; shows standard representations and broker details for planned disposal.

The notice provides the issuer, broker, quantity, acquisition method (stock option exercise), payment type (cash), and execution venue. It contains the usual signature attestation regarding material information and a blank remark section. From a governance perspective this is a standard Form 144 notification to satisfy Rule 144 requirements.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does CGON's Form 144 report?

The filing reports a proposed sale of 27,015 shares of CG Oncology common stock to be executed on 09/05/2025 on NASDAQ through Morgan Stanley Smith Barney LLC.

How were the shares acquired that are being sold?

The shares were acquired on 09/05/2025 by exercise of stock options from the issuer and payment was made in cash.

What is the aggregate market value reported for the proposed sale?

The aggregate market value of the shares to be sold is reported as $835,844.10.

Has the filer sold any CGON securities in the past three months?

The filing states "Nothing to Report" for securities sold during the past three months.

Who is the broker listed on the Form 144?

The broker is listed as Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.
CG Oncology, Inc.

NASDAQ:CGON

CGON Rankings

CGON Latest News

CGON Latest SEC Filings

CGON Stock Data

4.52B
73.31M
1.17%
112.6%
13.42%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
IRVINE